Our in vitro approach shows that the CD47 peptide agonists enable a Ca2+-mediated, caspase-independent PCD pathway that, sparing the normal T and B lymphocytes, efficiently kills CLL B cells, including those from drug-refractory patients (e.g., with dysfunctional TP53). This evidence concerns the gene CD47 and B-cell chronic lymphocytic leukemia.